Ignite Creation Date:
2024-05-06 @ 7:10 PM
Last Modification Date:
2024-10-26 @ 3:02 PM
Study NCT ID:
NCT05924243
Status:
COMPLETED
Last Update Posted:
2024-07-08
First Post:
2023-06-21
Brief Title:
A Study to Investigate The Safety Tolerability Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinsons Disease
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
A Phase 1b Adaptive Multi-Center Randomized Double Blind Placebo-Controlled Parallel Design Study to Investigate The Safety Tolerability Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multi-center randomized double blind adaptive parallel-group placebo controlled Phase 1b study to evaluate the safety tolerability pharmacokinetic PK and pharmacodynamics of RO7486967 in participants with idiopathic PD at the early stage of the disease modified HY stage 25 who are either treatment-naïve or on stable treatment with symptomatic therapy levodopa andor pramipexole ropinirole rotigotine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None